Stock IBT B INFANT BACTERIAL THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Infant Bacterial Therapeutics AB

Equities

IBT B

SE0008015259

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-06-27 EDT 		5-day change 1st Jan Change
99.4 SEK +2.47% Intraday chart for Infant Bacterial Therapeutics AB +0.81% +10.44%
05-07 Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02-08 Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023
Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Infant Bacterial Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Infant Bacterial Therapeutics AB Announces the Appointment of the Nomination Committee for the Annual General Meeting 2024
Infant Bacterial Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Infant Bacterial Therapeutics AB Announces Data Monitoring Committee Performs the Planned Safety Analysis of the Study Data of 1,403 Babies
Infant Bacterial Therapeutics AB Continues to Recruit Precious to Its Connection Study
Infant Bacterial Therapeutics AB Announces New Patent for Infant Bacterial Therapeutics Has Been Approved in Europe
Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023
Infant Bacterial Therapeutics Announces Opening of Final Infant Cohort Will Accelerate Patient Recruitment
Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2022
Infant Bacterial Therapeutics AB Publishes Clinical Findings in British Journal of Gastroenterology
Infant Bacterial Therapeutics AB Secures Platform for Pharma Grade Probiotic to Prevent Antibiotic Resistant Hospital Acquired Infections
Infant Bacterial Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Infant Bacterial Therapeutics AB Announces Nomination Committee Appointments
FDA Approves Infant Bacterial Therapeutics' Request for a New Orphan Drug Designation
Infant Bacterial Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IBT B Stock
  4. News Infant Bacterial Therapeutics AB
  5. Other languages